This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IceCure Medical 관리

관리 기준 확인 2/4

IceCure Medical CEO는 Eyal Shamir, Sep2016 에 임명되었습니다 의 임기는 6.83 년입니다. 총 연간 보상은 $ 658.24K, 71% 로 구성됩니다. 71% 급여 및 29% 보너스(회사 주식 및 옵션 포함). 는 ₪ 2.06M 가치에 해당하는 회사 주식의 1.06% 직접 소유합니다. 2.06M. 경영진과 이사회의 평균 재임 기간은 각각 4.6 년과 5.6 년입니다.

주요 정보

Eyal Shamir

최고 경영자

US$658.2k

총 보상

CEO 급여 비율	71.0%
CEO 임기	6.8yrs
CEO 소유권	1.1%
경영진 평균 재임 기간	4.6yrs
이사회 평균 재임 기간	5.6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Eyal Shamir 의 보수는 IceCure Medical 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2023	n/a	n/a	-US$16m
Dec 31 2022	US$658k	US$467k	-US$17m
Sep 30 2022	n/a	n/a	-US$16m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$13m
Dec 31 2021	US$489k	US$426k	-US$10m
Sep 30 2021	n/a	n/a	-US$8m
Jun 30 2021	n/a	n/a	-US$6m
Mar 31 2021	n/a	n/a	-US$4m
Dec 31 2020	US$420k	US$370k	-US$4m
Sep 30 2020	n/a	n/a	-US$4m
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	-US$4m
Dec 31 2019	n/a	n/a	-US$5m
Sep 30 2019	n/a	n/a	-US$5m
Jun 30 2019	n/a	n/a	-US$4m
Mar 31 2019	n/a	n/a	-US$4m
Dec 31 2018	US$350k	US$251k	-US$4m
Sep 30 2018	n/a	n/a	-US$3m
Jun 30 2018	n/a	n/a	-US$3m
Mar 31 2018	n/a	n/a	-US$3m
Dec 31 2017	US$312k	US$259k	-US$3m

보상 대 시장: Eyal 의 총 보상 ($USD 658.24K )은 IL 시장( $USD 427.00K ).

보상과 수익: 회사가 수익성이 없는 동안 Eyal 의 보상이 증가했습니다.

CEO

Eyal Shamir (62 yo)

6.8yrs

테뉴어

US$658,237

보상

Mr. Eyal Shamir serves as Chief Executive Officer and Director at IceCure Medical Ltd. since September 2016 and December 2017 respectively. Mr. Shamir served as Chief Executive Officer of Tadbik Pack Ltd.,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Eyal Shamir	CEO & Director	6.8yrs	US$658.24k	1.06% ₪ 2.1m
Ronen Tsimerman	CFO & COO	6.2yrs	US$474.89k	0.58% ₪ 1.1m
Tlalit Tel-Tzure	Vice President of Business Development & Global Marketing	4.6yrs	US$380.37k	0.26% ₪ 497.3k
Merav Dotan	Vice President of Human Resources	1.7yrs	US$282.17k	0.044% ₪ 85.8k
Galit Malik	Vice President of Operations & Service	less than a year	데이터 없음	0.074% ₪ 143.8k

4.6yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: ICCM 의 관리팀은 경험 ( 4.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Eyal Shamir	CEO & Director	5.6yrs	US$658.24k	1.06% ₪ 2.1m
Doron Birger	Independent Director	10.9yrs	데이터 없음	데이터 없음
Sharon Levita	Independent External Director	3.8yrs	US$205.58k	데이터 없음
Oded Tamir	Independent External Director	9.9yrs	데이터 없음	데이터 없음
Ron Mayron	Chairman of the Board	5.6yrs	US$62.23k	0.37% ₪ 724.4k
Chun Hung Chan	Independent Director	less than a year	데이터 없음	데이터 없음
Yang Huang	Director	3.3yrs	데이터 없음	0.086% ₪ 167.0k

5.6yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: ICCM 의 이사회는 경험(평균 재직 기간 5.6 년)으로 간주됩니다.

This company listing is no longer active

IceCure Medical 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Insufficient new directors

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

IceCure Medical Ltd, Annual General Meeting, Mar 03, 2022

Recent updates

Will IceCure Medical (TLV:ICCM) Spend Its Cash Wisely?

New major risk - Financial position

New major risk - Revenue and earnings growth

IceCure Medical Ltd to Report Q1, 2023 Results on May 22, 2023

Insufficient new directors

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.35 loss in FY 2021)

Here's Why We're Watching IceCure Medical's (TLV:ICCM) Cash Burn Situation

IceCure Medical Ltd Receives Notice of Allowance from the U.S. Patent and Trademark Office for Its Patent Application Titled Cryogen Pump

IceCure Medical Ltd Receives Notice of Patent Allowance in Japan for A Novel Cryogenic Pump for Its Next-Generation Cryoablation Systems

IceCure Medical Ltd Announces Interim Results from the ICESECRET Study for the Treatment of Patients with Small Renal Masses

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.091 loss in 3Q 2021)

IceCure Medical Ltd to Report Nine Months, 2022 Results on Dec 05, 2022

IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures

IceCure Medical Ltd. Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery

Are Investors Undervaluing IceCure Medical Ltd (TLV:ICCM) By 29%?

IceCure Medical Ltd Submits Regulatory Filing in Vietnam for Approval of Prosense®

Second quarter 2022 earnings released

IceCure Medical Ltd to Report Q2, 2022 Results on Aug 15, 2022

IceCure Medical Ltd Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors

IceCure Medical Ltd to Report Q1, 2022 Results on May 18, 2022

Full year 2021 earnings released: US$0.35 loss per share (vs US$0.27 loss in FY 2020)

Is IceCure Medical Ltd (TLV:ICCM) Potentially Undervalued?

IceCure Medical Ltd, Annual General Meeting, Mar 03, 2022

Icecure Medical Ltd Medical Receives Notice of Intention to Grant A European Patent Covering Its Cryogenic Pump

Is IceCure Medical (TLV:ICCM) In A Good Position To Deliver On Growth Plans?

IceCure Medical's Interim Results of the ICE3 Clinical Trial for Early-Stage Breast Cancer Cryoablation featured at the 2021 Annual Meeting of the Radiological Society of North America

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Icecure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the Ice3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer

Icecure Medical Ordinary Shares Deleted from Other OTC

IceCure Medical Ltd. Announces Positive Interim Results from ICE3 Clinical Trial for Breast Cancer Treatment by Freezing with the ProSense® Cryoablation System Presented at the 2021 ASBrS Meeting

Full year 2020 earnings released: ₪0.11 loss per share (vs ₪0.15 loss in FY 2019)

IceCure Signs Exclusive Distribution Agreement with Rise General Trading, LCC, Expanding Market Reach Across the Middle East

New 90-day high: ₪1.48

New 90-day high: ₪0.70

IceCure Medical Ltd Inks Expanded Distribution Agreement with Terumo Corporation for Thailand

New 90-day high: ₪0.72

IceCure Medical Ltd Expands Strategic Collaboration with Terumo Corporation, New Commercial Distribution Agreement Potentially Valued at over $7.0 Million

IceCure Medical Ltd has completed a Follow-on Equity Offering in the amount of ILS 20.7 million.

New 90-day low - ₪0.52

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령